May 7, 2021


Your News Buddy

He will receive $ 17 million for new treatment for epilepsy, neuropsychiatric electrocardiography

Current epilepsy medications do not work for all patients, and electrical stimulation offers another option to reduce seizures, but it is invasive. Initial neuroelectric therapy is developing and has a low invasive brain stimulation mechanism Raised $ 17.5 million That she was heading in the direction of her critical medical examination.

Neuroelectricians wear a transcranial cap on their head that triggers a transcranial electrical impulse. Called Startim, this device is an option for deep brain stimulation that requires surgery to place electrodes in certain areas of the brain.

Barcelona-based Nero Electric, based in Cambridge, Massachusetts, has recently completed a small project. Experimental study Evaluate the ability to treat patients with low-grade epilepsy – epilepsy that does not respond to drug treatment. An open-label study reported 20 adults and children who were allowed to continue taking pesticides. Patients received starch treatment for 10 sessions in two weeks. The ultimate goal was to reduce the frequency of seizures over the past eight weeks.

According to neuro electrocution, patients in the pilot study had a 44% reduction in seizures compared with baseline. The incidence of seizures was more than 75% in four patients. Neuro Electric now plans to test the device on a larger scale. A double-blind study As a controlled treatment. The critical study is expected to enroll about 190 patients who are randomly assigned to receive 10 sessions of stasis or hypothetical treatment in two weeks. Those patients followed for another 10 weeks. As a pilot study, the main goal is to measure the frequency of seizures.

In the United States, starch is classified as a test. In Europe it is only allowed for research. The device is based on the Enbio EGA and has previously been offered in the field of neurosurgery FDA filter in 2017. Like sturgeon, Enobio is a hat worn on his head. The electrodes in the device collect the electroencephalogram (ECG) signals and transmit data via the company software to the computer via WiFi. The device has been developed for use by physicians in medical clinics; Neuroelectricity is sold for research purposes. Staphylococcus aureus contains endogenous EEG components that increase transcranial electrical stimulation.

Neuroelectricians are not the only medical device trying to improve the way epilepsy is treated. Mountain View, California-based Neuropex has developed a device that monitors, analyzes, and responds to a patient’s brain’s electrical activity. In late April. Neuropus IPO raised $ 102 millionHe said the company would use it to expand its sales and marketing efforts and support additional R&D.

Startstim’s basic study on epilepsy is expected to begin in the third quarter of this year. A special experimental study of neuroelectrical therapy is already underway in patients with major depressive disorder who have not responded to drug treatment. These patients are being evaluated at home. Neuroelectric therapy may be offered at home during the epidemic, as the study is intended for patients who are partially motivated for other forms of neurometrodynamic therapy. The study was conducted by researchers at Harvard University.

A series of grants announced on Tuesday were funded by the MorningSide Ventures. According to MorningSide Stephen Bruce, neurosurgeons can offer a way to overcome drug limitations.

Instead of focusing on one target and one receptor, we believe that neurotransmitters can be used to treat symptoms that traditional medicine has little or no effect on, as the central nervous system is being manipulated using the brain’s natural signals. Prepared statement.

YouTube video screenshot for Startstim medical device